The emerging role of the androgen receptor in bladder cancer

Endocrine-Related Cancer

Volumn 22, Issue 5, 2015, Pages R265-R277

  Lombard, Alan P ^a,b,c   Mudryj, Maria ^a,b  

^a VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Androgen receptor; Bladder cancer; Endocrine therapy

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; AR PROTEIN, HUMAN;

ANGIOGENESIS; BLADDER CANCER; BLADDER CARCINOGENESIS; BLADDER FUNCTION; CANCER GROWTH; GENETIC VARIABILITY; HUMAN; META ANALYSIS (TOPIC); MOLECULARLY TARGETED THERAPY; NONHUMAN; ORGANOGENESIS; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TUMOR INVASION; UROTHELIAL DEVELOPMENT; CHEMISTRY; DISEASE COURSE; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PATHOLOGY; URINARY BLADDER NEOPLASMS;

ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MOLECULAR TARGETED THERAPY; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 84942084419     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-15-0209     Document Type: Review

References (103)

1. Ahmadi N, Delprado WJ, Brooks AJ, Brenner PC, Coombes GM, Grant A & Patel MI 2014 Cancer identified incidentally in the prostate following radical cystoprostatectomy: an Australian study. ANZ Journal of Surgery 84 473-476. (doi:10.1111/ans.12015)
2. Allen RC, Zoghbi HY, Moseley AB, Rosenblatt HM & Belmont JW 1992 Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. American Journal of Human Genetics 51 1229-1239. (doi:10.3892/or-00000702)
3. Alsinnawi M, Loftus B, Flynn R, McDermott T, Grainger R & Thornhill JA 2012 The incidence and relevance of prostate cancer in radical cystoprostatectomy specimens. International Urology and Nephrology 44 1705-1710. (doi:10.1007/s11255-012-0224-y)
4. Armstrong LC & Bornstein P 2003 Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biology 22 63-71. (doi:10.1016/S0945-053X(03)0005-2)
5. Augello MA,BurdCJ, Birbe R,McNairC, ErtelA, MageeMS, Frigo DE, Wilder-Romans K, Shilkrut M, Han S et al. 2013 Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes. Journal of Clinical Investigation 123 493-508. (doi:10.1172/JCI64750)
6. Bevers RF, de Boer EC, Kurth KH & Schamhart DH 1998 BCG-induced interleukin-6 upregulation and BCG internalization in well and poorly differentiated human bladder cancer cell lines. European Cytokine Network 9 181-186.
7. Bock KW 2010 Functions and transcriptional regulation of adult human hepatic UDP-glucuronosyl-transferases (UGTs): mechanisms responsible for interindividual variation of UGT levels. Biochemical Pharmacology 80 771-777. (doi:10.1016/j.bcp.2010.04.034)
8. Boorjian S, Ugras S, Mongan NP, Gudas LJ, You X, Tickoo SK & Scherr DS 2004 Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology 64 383-388. (doi:10.1016/j.urology.2004.03.025)
9. Boorjian SA, Heemers HV, Frank I, Farmer SA, Schmidt LJ, Sebo TJ & Tindall DJ 2009 Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder. Endocrine-Related Cancer 16 123-137. (doi:10.1677/ERC-08-0124)
10. Bruins HM, Djaladat H, Ahmadi H, Sherrod A, Cai J, Miranda G, Skinner EC & Daneshmand S 2013 Incidental prostate cancer in patients with bladder urothelial carcinoma: comprehensive analysis of 1,476 radical cystoprostatectomy specimens. Journal of Urology 190 1704-1709. (doi:10.1016/j.juro.2013.05.034)
11. Cancer Genome Atlas Research Network 2014 Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507 315-322. (doi:10.1038/nature12965)
12. Carneiro BA, Meeks JJ, Kuzel TM, Scaranti M, Abdulkadir SA & Giles FJ 2015 Emerging therapeutic targets in bladder cancer. Cancer Treatment Reviews 41 170-178. (doi:10.1016/j.ctrv.2014.11.003)
13. Chang CS, Kokontis J & Liao ST 1988 Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 240 324-326. (doi:10.1126/science.3353726)
14. Chang C, Lee SO, Yeh S & Chang TM 2014 Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene 33 3225-3234. (doi:10.1038/onc.2013.274)
15. Chen F, Langenstroer P, Zhang G, Iwamoto Y & See W 2003 Androgen dependent regulation of bacillus Calmette-Guerin induced interleukin-6 expression in human transitional carcinoma cell lines. Journal of Urology 170 2009-2013. (doi:10.1097/01.ju.0000092238.15685.10)
16. Cheng L,MacLennan GT, Pan CX, Jones TD, Moore CR, Zhang S, Gu J, Patel NB, Kao C & Gardner TA 2004 Allelic loss of the active X chromosome during bladder carcinogenesis. Archives of Pathology & Laboratory Medicine 128 187-190.
17. Crallan RA, Georgopoulos NT & Southgate J 2006 Experimental models of human bladder carcinogenesis. Carcinogenesis 27 374-381. (doi:10.1093/carcin/bgi266)
18. Culig Z & Santer FR 2012 Androgen receptor co-activators in the regulation of cellular events in prostate cancer. World Journal of Urology 30 297-302. (doi:10.1007/s00345-011-0797-6)
19. Devlin HL & Mudryj M 2009 Progression of prostate cancer: multiple pathways to androgen independence. Cancer Letters 274 177-186. (doi:10.1016/j.canlet.2008.06.007)
20. Fritsche HM, Aziz A, Eder F, Otto W, Denzinger S, Wieland WF, May M, Hofstadter F, Hartmann A & Burger M 2012 Potentially clinically relevant prostate cancer is found more frequently after complete than after partial histopathological processing of radical cystoprostatectomy specimens. Virchows Archiv 461 655-661. (doi:10.1007/s00428-012-1328-6)
21. Fu YP, Kohaar I, Rothman N, Earl J, Figueroa JD, Ye Y, Malats N, Tang W, Liu L, Garcia-ClosasMet al. 2012 Common genetic variants in the PSCA gene influence gene expression and bladder cancer risk. PNAS 109 4974-4979. (doi:10.1073/pnas.1202189109)
22. Gakis G & Stenzl A 2013 Gender-specific differences in muscle-invasive bladder cancer: the concept of sex steroid sensitivity. World Journal of Urology 31 1059-1064. (doi:10.1007/s00345-013-1037-z)
23. Gao L, Schwartzman J, Gibbs A, Lisac R, Kleinschmidt R, Wilmot B, Bottomly D, Coleman I, Nelson P, McWeeney S et al. 2013 Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation. PLoS ONE 8 e63563. (doi:10.1371/journal. pone.0063563)
24. Garcia-Closas M, Ye Y, Rothman N, Figueroa JD, Malats N, Dinney CP, Chatterjee N, Prokunina-Olsson L,Wang Z, Lin J et al. 2011 A genomewide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. Human Molecular Genetics 20 4282-4289. (doi:10.1093/hmg/ddr342)
25. Golka K, Selinski S, Lehmann ML, Blaszkewicz M, Marchan R, Ickstadt K, Schwender H, Bolt HM& Hengstler JG 2011 Genetic variants in urinary bladder cancer: collective power of the "wimp SNPs". Archives of Toxicology 85 539-554. (doi:10.1007/s00204-011-0676-3)
26. Gonzalez-Zulueta M, Ruppert JM, Tokino K, Tsai YC, Spruck CH III, Miyao N, Nichols PW, Hermann GG, Horn T, Steven K et al. 1993 Microsatellite instability in bladder cancer. Cancer Research 53 5620-5623.
27. Hartge P, Harvey EB, Linehan WM, Silverman DT, Sullivan JW, Hoover RN & Fraumeni JF Jr 1990 Unexplained excess risk of bladder cancer in men. Journal of the National Cancer Institute 82 1636-1640. (doi:10.1093/jnci/82.20.1636)
28. Higano CS 2003 Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 61 32-38. (doi:10.1016/S0090-4295(02)2397-X)
29. Hsieh TF, Chen CC, Ma WL, Chuang WM, Hung XF, Tsai YR, Lin MH, Zhang Q, Zhang C, Chang C et al. 2013 Epidermal growth factor enhances androgen receptormediated bladder cancer progression and invasion via potentiation of AR transactivation. Oncology Reports 30 2917-2922. (doi:10.3892/or.2013.2792)
30. Hsu JW, Hsu I, Xu D, Miyamoto H, Liang L, Wu XR, Shyr CR & Chang C 2013 Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor. American Journal of Pathology 182 1811-1820. (doi:10.1016/j.ajpath.2013.01.018)
31. Huppi K, Pitt JJ, Wahlberg BM & Caplen NJ 2012 The 8q24 gene desert: an oasis of non-coding transcriptional activity. Frontiers in Genetics 3 69. (doi:10.3389/fgene.2012.00069)
32. Imada S, Akaza H, Ami Y, Koiso K, Ideyama Y & Takenaka T 1997 Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats. European Urology 31 360-364.
33. Izumi K, Zheng Y, Li Y, Zaengle J & Miyamoto H 2012 Epidermal growth factor induces bladder cancer cell proliferation through activation of the androgen receptor. International Journal of Oncology 41 1587-1592. (doi:10.3892/ijo.2012.1593)
34. Izumi K, Zheng Y, Hsu JW, Chang C & Miyamoto H 2013 Androgen receptor signals regulate UDP-glucuronosyltransferases in the urinary bladder: a potential mechanism of androgen-induced bladder carcinogenesis. Molecular Carcinogenesis 52 94-102. (doi:10.1002/mc.21833)
35. Izumi K, Taguri M, Miyamoto H, Hara Y, Kishida T, Chiba K, Murai T, Hirai K, Suzuki K, Fujinami K et al. 2014 Androgen deprivation therapy prevents bladder cancer recurrence. Oncotarget 5 12665-12674.
36. Jain A, Lam A, Vivanco I, CareyMF & Reiter RE 2002 Identification of an androgen-dependent enhancer within the prostate stemcell antigen gene.Molecular Endocrinology 16 2323-2337. (doi:10.1210/me.2002-0004)
37. Jing Y, Cui D, Guo W, Jiang J, Jiang B, Lu Y, Zhao W, Wang X, Jiang Q, Han B et al. 2014 Activated androgen receptor promotes bladder cancer metastasis via Slugmediated epithelial-mesenchymal transition. Cancer Letters 348 135-145. (doi:10.1016/j.canlet.2014.03.018)
38. Jitao W, Jinchen H, Qingzuo L, Li C, Lei S, Jianming W & Zhenli G 2014 Androgen receptor inducing bladder cancer progression by promoting an epithelial-mesenchymal transition. Andrologia 46 1128-1133. (doi:10.1111/and.12203)
39. Johnson AM, O'Connell MJ, Miyamoto H, Huang J, Yao JL, Messing EM & Reeder JE 2008 Androgenic dependence of exophytic tumor growth in a transgenicmousemodel of bladder cancer: a role for thrombospondin-1. BMC Urology 8 7. (doi:10.1186/1471-2490-8-7)
40. Kauffman EC, Robinson BD, Downes MJ, Powell LG, Lee MM, Scherr DS, Gudas LJ & Mongan NP 2011 Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Molecular Carcinogenesis 50 931-944. (doi:10.1002/mc.20758)
41. Kazemi-Esfarjani P, Trifiro MA & Pinsky L 1995 Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: possible pathogenetic relevance for the (CAG)n-expanded neuronopathies. Human Molecular Genetics 4 523-527. (doi:10.1093/hmg/4.4.523)
42. Keast JR & Saunders RJ 1998 Testosterone has potent, selective effects on the morphology of pelvic autonomic neurons which control the bladder, lower bowel and internal reproductive organs of the male rat. Neuroscience 85 543-556. (doi:10.1016/S0306-4522(97)0631-3)
43. Kiemeney LA, Thorlacius S, Sulem P, Geller F, Aben KK, Stacey SN, Gudmundsson J, Jakobsdottir M, Bergthorsson JT, Sigurdsson A et al. 2008 Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nature Genetics 40 1307-1312. (doi:10.1038/ng.229)
44. Kim JJ 2012 Recent advances in treatment of advanced urothelial carcinoma. Current Urology Reports 13 147-152. (doi:10.1007/s11934-012-0238-0)
45. Kim T, Cui R, Jeon YJ, Lee JH, Sim H, Park JK, Fadda P, Tili E, Nakanishi H, Huh MI et al. 2014 Long-range interaction and correlation between MYC enhancer and oncogenic long noncoding RNA CARLo-5. PNAS 111 4173-4178. (doi:10.1073/pnas.1400350111)
46. Kimura N, Mizokami A, Oonuma T, Sasano H & Nagura H 1993 Immunocytochemical localization of androgen receptor with polyclonal antibody in paraffin-embedded human tissues. Journal of Histochemistry and Cytochemistry 41 671-678. (doi:10.1177/41.5. 8468448)
47. Knowles MA & Hurst CD 2015 Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nature Reviews. Cancer 15 25-41. (doi:10.1038/nrc3817)
48. Koutros S, Baris D, Fischer A, Tang W, Garcia-Closas M, Karagas MR, Schwenn M, Johnson A, Figueroa J, Waddell R et al. 2013 Differential urinary specific gravity as a molecular phenotype of the bladder cancer genetic association in the urea transporter gene, SLC14A1. International Journal of Cancer 133 3008-3013. (doi:10.1002/ijc.28325)
49. Lamont KR & Tindall DJ 2011 Minireview: Alternative activation pathways for the androgen receptor in prostate cancer. Molecular Endocrinology 25 897-907. (doi:10.1210/me.2010-0469)
50. Laor E, Schiffman ZJ, Braunstein JD, Reid RE, Tolia BM, Koss LG & Freed SZ 1985 Androgen receptors in bladder tumors. Urology 25 161-163. (doi:10.1016/0090-4295(85)0534-5)
51. Li Y, Zheng Y, Izumi K, Ishiguro H, Ye B, Li F &Miyamoto H 2013 Androgen activates b-catenin signaling in bladder cancer cells. Endocrine-Related Cancer 20 293-304. (doi:10.1530/ERC-12-0328)
52. Lin C, Yin Y, Stemler K, Humphrey P, Kibel AS, Mysorekar IU & Ma L 2013 Constitutive b-catenin activation induces male-specific tumorigenesis in the bladder urothelium. Cancer Research 73 5914-5925. (doi:10.1158/0008-5472.CAN-12-4198)
53. Lubahn DB, Joseph DR, Sullivan PM, Willard HF, French FS & Wilson EM 1988 Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science 240 327-330. (doi:10.1126/science.3353727)
54. Luo J, Tang L, Zhang J, Ni J, Zhang HP, Zhang L, Xu JF& Zheng D 2014 Long non-coding RNA CARLo-5 is a negative prognostic factor and exhibits tumor pro-oncogenic activity in non-small cell lung cancer. Tumour Biology 35 11541-11549. (doi:10.1007/s13277-014-2442-7)
55. Malkowicz SB 2000 Intravesical therapy for superficial bladder cancer. Seminars in Urologic Oncology 18 280-288.
56. Marcinkiewicz K, Scotland KB, Boorjian SA, Nilsson EM, Persson JL, Abrahamsson PA, Allegrucci C, Hughes IA, Gudas LJ & Mongan NP 2012 The androgen receptor and stem cell pathways in prostate and bladder cancers (review). International Journal of Oncology 40 5-12. (doi:10.3892/ijo.2011.1212)
57. Mashhadi R, Pourmand G, Kosari F, Mehrsai A, Salem S, Pourmand MR, Alatab S, Khonsari M, Heydari F, Beladi L et al. 2014 Role of steroid hormone receptors in formation and progression of bladder carcinoma: a case-control study. Urology Journal 11 1968-1973.
58. Matsuda K, Takahashi A, Middlebrooks CD, Obara W, Nasu Y, Inoue K, Tamura K, Yamasaki I, Naya Y, Tanikawa C et al. 2015 Genome-wide association study identified SNP on 15q24 associated with bladder cancer risk in Japanese population. Human Molecular Genetics 24 1177-1184. (doi:10.1093/hmg/ddu512)
59. Matsuki K, Akaza H, Munakata A, Kameyama S & Aso Y 1989 Effects of LH-RH analogue on pituitary-testicular axis and bladder carcinogenesis of BBN administered male rats. Nihon Hinyokika Gakkai Zasshi. The Japanese Journal of Urology 80 1051-1058. (doi:10.5980/jpnjurol1989. 80.1051)
60. Matsuki K, Akaza H & Aso Y 1992 Effects of luteinizing hormone-releasing hormone agonist on bladder carcinogenesis in male rats. Nihon Hinyokika Gakkai Zasshi. The Japanese Journal of Urology 83 1452-1458. (doi:10.5980/jpnjurol1989.83.1452)
61. Mir C, Shariat SF, van der Kwast TH, Ashfaq R, Lotan Y, Evans A, Skeldon S, Hanna S, Vajpeyi R, Kuk C et al. 2011 Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. BJU International 108 24-30. (doi:10.1111/j.1464-410X.2010.09834.x)
62. Miyamoto H, Yang Z, Chen YT, Ishiguro H, Uemura H, Kubota Y, Nagashima Y, Chang YJ, Hu YC, Tsai MY et al. 2007 Promotion of bladder cancer development and progression by androgen receptor signals. Journal of the National Cancer Institute 99 558-568. (doi:10.1093/jnci/djk113)
63. Miyamoto H, Yao JL, Chaux A, Zheng Y, Hsu I, Izumi K, Chang C, Messing EM, Netto GJ & Yeh S 2012 Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU International 109 1716-1726. (doi:10.1111/j.1464-410X.2011.10706.x)
64. Mizuno T 1994 Aspects of morphogenesis and cytodifferentiation of endoderm offered by organ culture techniques. International Journal of Developmental Biology 38 267-272.
65. Mohanty SK, Smith SC, Chang E, Luthringer DJ, Gown AM, Aron M & Amin MB 2014 Evaluation of contemporary prostate and urothelial lineage biomarkers in a consecutive cohort of poorly differentiated bladder neck carcinomas. American Journal of Clinical Pathology 142 173-183. (doi:10.1309/AJCPK1OV6IMNPFGL)
66. Mudryj M & Tepper CG 2013 On the origins of the androgen receptor low molecular weight species. Hormones & Cancer 4 259-269. (doi:10.1007/s12672-013-0152-z)
67. Nakamura A, Nakajima M, Yamanaka H, Fujiwara R & Yokoi T 2008 Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metabolism and Disposition: The Biological Fate of Chemicals 36 1461-1464. (doi:10.1124/dmd.108.021428)
68. Nevoux P, Ouzzane A, Ahmed HU, EmbertonM, Montironi R, Presti JC Jr & Villers A 2012 Quantitative tissue analyses of prostate cancer foci in an unselected cystoprostatectomy series. BJU International 110 517-523. (doi:10.1111/j.1464-410X.2011.10776.x)
69. Noronha RF & Rao BR 1986 Sex hormone receptors in localized and advanced transitional cell carcinoma of urinary tract in humans. Urology 28 401-403. (doi:10.1016/0090-4295(86)0073-7)
70. Okajima E, Hiramatsu T, Iriya K, IjuinM& Matsushima S 1975 Effects of sex hormones on development of urinary bladder tumours in rats induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. Urological Research 3 73-79. (doi:10.1007/BF00256185)
71. Overdevest JB, Knubel KH, Duex JE, Thomas S, Nitz MD, Harding MA, Smith SC, Frierson HF, Conaway M & Theodorescu D 2012 CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulated. PNAS 109 E3588-E3596. (doi:10.1073/pnas.1113960109)
72. Petre-Draviam CE, Cook SL, Burd CJ, Marshall TW, Wetherill YB & Knudsen KE 2003 Specificity of cyclin D1 for androgen receptor regulation. Cancer Research 63 4903-4913.
73. Pour PM & Stepan K 1987 Induction of prostatic carcinomas and lower urinary tract neoplasms by combined treatment of intact and castrated rats with testosterone propionate and N-nitrosobis(2-oxopropyl)amine. Cancer Research 47 5699-5706.
74. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL et al. 2014 MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515 558-562. (doi:10.1038/nature13904)
75. Proverbs-Singh T, Feldman JL, Morris MJ, Autio KA & Traina TA 2015 Targeting the androgen receptor in prostate and breast cancer: several new agents in development. Endocrine-Related Cancer 22 R87-R106. (doi:10.1530/ERC-14-0543)
76. Rafnar T, Vermeulen SH, Sulem P, Thorleifsson G, Aben KK, Witjes JA, Grotenhuis AJ,VerhaeghGW,Hulsbergen-vande Kaa CA, Besenbacher S et al. 2011 European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. Human Molecular Genetics 20 4268-4281. (doi:10.1093/hmg/ddr303)
77. Ren B, Li W, Yang Y & Wu S 2014 The impact of cyclin D1 overexpression on the prognosis of bladder cancer: a meta-analysis. World Journal of Surgical Oncology 12 55. (doi:10.1186/1477-7819-12-55)
78. Ruizeveld de Winter JA, Trapman J, Vermey M, Mulder E, Zegers ND & van der Kwast TH 1991 Androgen receptor expression in human tissues: an immunohistochemical study. Journal of Histochemistry and Cytochemistry 39 927-936. (doi:10.1177/39.7.1865110)
79. Saikawa S, Kanamura H, Noriki S, Matsukawa S & Okada K 2001 The effects of organ resection on rat urinary bladder carcinogenesis. Urological Research 29 210-215. (doi:10.1007/s002400100184)
80. Salmi S, Santti R, Gustafsson JA & Makela S 2001 Co-localization of androgen receptor with estrogen receptor b in the lower urinary tract of the male rat. Journal of Urology 166 674-677. (doi:10.1016/S0022-5347(05)6041-7)
81. Schmitz-Drager BJ, Schulz WA, Jurgens B, Gerharz CD, vanRoeyen CR, Bultel H, Ebert T & Ackermann R 1997 c-myc in bladder cancer. Clinical findings and analysis of mechanism. Urological Research 25 (Suppl 1) S45-S49. (doi:10.1007/BF00942047)
82. Shiota M, Takeuchi A, Yokomizo A, Kashiwagi E, Tatsugami K, Kuroiwa K & Naito S 2012 Androgen receptor signaling regulates cell growth and vulnerability to doxorubicin in bladder cancer. Journal of Urology 188 276-286. (doi:10.1016/j.juro.2012.02.2554)
83. Shortliffe LM, Ye Y, Behr B & Wang B 2014 Testosterone changes bladder and kidney structure in juvenile male rats. Journal of Urology 191 1913-1919. (doi:10.1016/j.juro.2014.01.012)
84. Siegel R, Naishadham D & Jemal A 2012 Cancer statistics, 2012. CA: A Cancer Journal for Clinicians 62 10-29. (doi:10.3322/caac.20138)
85. Singh V, Jaiswal PK & Mittal RD 2014 Replicative study of GWAS TP63C/T, TERTC/T, and SLC14A1C/T with susceptibility to bladder cancer in North Indians. Urologic Oncology 32 1209-1214. (doi:10.1016/j.urolonc. 2014.05.013)
86. Sun Y, Wang BE, Leong KG, Yue P, Li L, Jhunjhunwala S, Chen D, Seo K, Modrusan Z, Gao WQ et al. 2012 Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Research 72 527-536. (doi:10.1158/0008-5472.CAN-11-3004)
87. Teng XY, Liu GQ, Diao XL, Wu ZY, Li L, Zhang W, Zhang X & Su Q 2010 CAG repeats in the androgen receptor gene are shorter in patients with pulmonary, esophageal or bladder carcinoma and longer in women with uterine leiomyoma. Oncology Reports 23 811-818. (doi:10.3892/or-0000070)
88. Terada S, Suzuki N, Uchide K, Akasofu K & Nishida E 1992 Effect of testosterone on the development of bladder tumors and calculi in female rats. Gynecologic and Obstetric Investigation 34 105-110. (doi:10.1159/000292737)
89. Thomas JC, Oottamasathien S, Makari JH, Honea L, Sharif-Afshar AR, Wang Y, Adams C, Wills ML, Bhowmick NA, Adams MC et al. 2008 Temporal-spatial protein expression in bladder tissue derived from embryonic stem cells. Journal of Urology 180 1784-1789. (doi:10.1016/j.juro.2008.03.098)
90. Trapman J, Klaassen P, Kuiper GG, van der Korput JA, Faber PW, van Rooij HC, Geurts van Kessel A, Voorhorst MM, Mulder E & Brinkmann AO 1988 Cloning, structure and expression of a cDNA encoding the human androgen receptor. Biochemical and Biophysical Research Communications 153 241-248. (doi:10.1016/S0006-291X(88)1214-2)
91. Turkeri LN, Erton ML, Cevik I & Akdas A 1998 Impact of the expression of epidermal growth factor, transforming growth factor a, and epidermal growth factor receptor on the prognosis of superficial bladder cancer. Urology 51 645-649. (doi:10.1016/S0090-4295(97)00648-1)
92. Tuygun C, Kankaya D, Imamoglu A, Sertcelik A, Zengin K, Oktay M & Sertcelik N 2011 Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: a comparative analysis of clinicopathological features and survival outcomes according to receptor expression. Urologic Oncology 29 43-51. (doi:10.1016/j. urolonc.2009.01.033)
93. Vaarala MH, Hirvikoski P, Kauppila S & Paavonen TK 2012 Identification of androgen-regulated genes in human prostate. Molecular Medicine Reports 6 466-472. (doi:10.3892/mmr.2012.95)
94. WangM, Zhang W, Yuan L, Fu G, Wei Q & Zhang Z 2009 Common genetic variants on 8q24 contribute to susceptibility to bladder cancer in a Chinese population. Carcinogenesis 30 991-996. (doi:10.1093/carcin/bgp091)
95. Wen J, Li HZ, Ji ZG & Jin J 2015 Human urothelial carcinoma cell response to Sunitinib malate therapy in vitro. Cancer Cell International 15 26. (doi:10.1186/s12935-015-0179-z)
96. Williams EM, Higgins JP, Sangoi AR, McKenney JK & Troxell ML 2015 Androgen receptor immunohistochemistry in genitourinary neoplasms. International Urology and Nephrology 47 81-85. (doi:10.1007/s11255-014-0834-7)
97. Wu X, Ye Y, Kiemeney LA, Sulem P, Rafnar T, Matullo G, Seminara D, Yoshida T, Saeki N, Andrew AS et al. 2009 Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nature Genetics 41 991-995. (doi:10.1038/ng.421)
98. Wu JT, Han BM, Yu SQ, Wang HP & Xia SJ 2010 Androgen receptor is a potential therapeutic target for bladder cancer. Urology 75 820-827. (doi:10.1016/j.urology.2009.10.041)
99. Zhang GJ, Crist SA, McKerrow AK, Xu Y, Ladehoff DC & See WA 2000 Autocrine IL-6 production by human transitional carcinoma cells upregulates expression of the a5b1 firbonectin receptor. Journal of Urology 163 1553-1559. (doi:10.1016/S0022-5347(05)7678-1)
100. Zhang Y, Ma M, Liu W, DingW& Yu H 2014 Enhanced expression of long noncoding RNA CARLo-5 is associated with the development of gastric cancer. International Journal of Clinical and Experimental Pathology 7 8471-8479.
101. Zheng Y, Izumi K, Yao JL & Miyamoto H 2011 Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells. Endocrine-Related Cancer 18 451-464. (doi:10.1530/ERC-11-0010)
102. Zhu W, Zhang JS & Young CY 2001 Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP. Carcinogenesis 22 1399-1403. (doi:10.1093/carcin/22.9.1399)
103. Zhuang YH, Blauer M, Tammela T & Tuohimaa P 1997 Immunodetection of androgen receptor in human urinary bladder cancer. Histopathology 30 556-562. (doi:10.1046/j.1365-2559.1997.5610801.x)